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Studies examining Abelson/Moloney murine leukemia virus [A-MuLV(Mo)]-
induced leukemia in mice have revealed that there is a marked variation in the
susceptibility to disease among commonly used inbred strains of mice (1). While
nearly all strains examined develop characteristic disease symptoms afterinjection
of newborn mice with the virus, most mouse strains are resistant when inoculated
as adults. For example, C3H/HeN and C57BL/6 mice are almost completely
resistant to tumor induction as adults, BALB/c and DBA/2 mice are among the
most susceptible strains, and A/J mice show an intermediate- to low-level inci-
dence. Although two susceptibility loci have been identified using inbred and
hybrid mouse strains, the mechanism of tumor resistance remain unknown.
We have previously described the appearance of a cell surface glycoprotein,
gp160", at high levels on virtually all in vitro (2) and in vivo (3) Abelson MuLV
(A-MuLV)-induced B lineage tumors. After in vivo infection with A-MuLV(Mo),
susceptible hosts develop a lymphoid replacement of the bone marrow, spleno-
megaly, and often lymphadenopathy, all due to proliferation and spread of
malignant cells (4). We have shown (3) that the antigen 6C3Ag marks these cells
and that the 6C3Ag+ cells score as transformed clonogenic cells in an in vitro
agar colony assay. Because it was possible that one or more A-MuLV(Mo)
resistance genes acts before or after expression of 6C3Ag on infectecd cells, we
undertook an examination of the mouse strain distribution of expression of
6C3Ag on cells of A-MuLV(Mo)-infected hosts.
In this report we show that strains that are not susceptible to disease when
injected as adults do not develop cells expressing high levels of 6C3Ag. In fact,
expression of 6C3Ag by bone marrow, lymph node, or spleen cells is confined
to diseased animals in susceptible strains. These data support our conclusion that
high-level 6C3Ag expression is specific for the population of lymphocytes trans-
formed by the virus in diseased animals, and supports the hypothesis that
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FIGURE 1 . Percentage of 6C3Ag" bone marrow cells in various strains of inbred mice
exposed to A-MuLV(Mo) . At 3.5 wk (left) or 8 wk (right) after birth, various strains of inbred
mice were injected i.v . with a lethal dose of A-MuLV(Mo) . Mice from each groupwere killed
when disease symptoms became apparent (young DBA/2 mice), or at4wk (striped bars), 8wk
(shaded bars), or 12 wk (open bars) (in the case of the mice injected at 8 wk of age). Numbers
above each bar indicate the percentage of cells that stain with mAb 6C3 above that found in
bone marrow of uninjected mice . Numbers in parenthesis below strain designation represent
the number of animals that developed disease symptoms or died, and the number of animals
injected . One A/J mouse died before an analysis could be done, therefore that mouse is not
represented in this data .
expression of the antigen-bearing proteins at high levels may be necessary for
growth of A-MuLV(Mo) tumors in vivo .
Materials and Methods
Mice. All inbred mice were bred at mouse colonies at Stanford University . The
recombinant inbred mice CxB.H and CxB.G were purchased from The Jackson Labora-
tories, Bar Harbor,ME .
Reagents.
￿
mAb 6C3 has been described previously (2, 3) . Goat anti-rat Ig was purified
from serum purchased from PelFreez (Rogers, AR) by protein A chromatography, and
was subsequently conjugated to FITC by the method of Goding (5) .
Staining.
￿
Immunofluorescent stainings and FACS analysis were carried out as previ-
ously described (3) .
Virus. Virus was harvested from confluent, clonal Moloney MuLV (M-MuLV)-pro-
ducing cells originally provided byO . N. Witte (Molecular Biology Institute, University
ofCalifornia, LosAngeles) . This virus was then used to rescue the A-MuLV genome from
a confluent culture ofANN- I cells, a procedure resulting in A-MuLV(Mo) .
Results
6C3Ag" Cells AreFoundOnly in BoneMarrow Cell SuspensionsfromA-MuLV(Mo)-
infected Mice Known to Be Susceptible to Disease . To test the correlation between
Abelson disease and the appearance of cells expressing high levels of 6C3Ag
(6C3Agh ' cells), we injected a high-disease susceptibility mouse strain (DBA/2)
and several low-susceptibility mouse strains (C3H/HeN, C57BL/6, A/J) with A-
MuLV(Mo) (1) . In addition, we injected two different ages of DBA/2 and
C57BL/6 mice ; 3.5 wk and 8 wk after birth . Fig . I (left) shows that only DBA/2
mice injected 3-4 wk after birth develop Abelson disease symptoms and that
only 3-4-wk-old DBA/2 mice developed 6C3Agh ' bone marrow cells . 8-wk-old
DBA/2 mice did not succumb to the virus and did not develop a significant
percentage of 6C3Agh ' cells in bone marrow (Fig. 1, right) . A low percentage
(2%) of6C3Agh ' cellswere found in one olderDBA/2 mouse, which could reflect
incipient disease . From this and other (3) experiments, there appears to be a1358
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FIGURE 2. Appearance of 6C3Ag" cells corresponds to Abelson disease susceptibility in
recombinant inbred strains. CxB.G (A) and CxB.H (B) mice were injected at 3.5 wk of age,
and each was killed 4 wk later when the CxB.H mice showed signs of Abelson disease. The
CxB.G mouse appeared normal, with none of the disease symptoms obvious in the CxB.H
mouseanalyzed in B.
complete correlation between disease and high-level expression of 6C3Ag on a
high percentage of bone marrow cells.
6C3Ag" Cells Are Found Only in Recombinant Strains that Succumb to Abelson
Disease. As a further testofthe hypothesis that 6C3Agh'expression is completely
associated with the Abelson disease state and that genetic restrictions to A-
MuLV(Mo) leukemogenesis prevent appearance of6C3Agh' cells, A-MuLV(Mo)
was injected i.v. into disease-resistantand -susceptible recombinant inbred strains.
These animals were derived from inbreeding pairs of (C57BL/6 X BALB/c)F2
(CxB) mice. As published (1), CxB.G is resistant to tumor induction while CxB.H
is relatively susceptible (1). 3 wk after injection, CxB.H mice begin to develop
signs of tumor, whereas CxB.G appeared normal . At this time, one injected
animal of each strain was killed, and a bone marrow cell suspension was made
and stained with mAb6C3. Fig. 2A is the FACS profile derived from analysis of
immunofluorescent staining of a CxB.G mouse, while Fig. 2B represents the
profile from the diseased CxB.H strain ; only the CxB.H (susceptible) mouse
showed 6C3Agh' cells. Thus the appearance of 6C3Agh' cells is predictive of the
diseased state and genetic susceptibility to the disease. In total, three CxB.H
mice with symptoms of Abelson disease were analyzed for 6C3Ag, and all display
this pattern ofexpression (Fig. 2B). With a longer latency, some of the CxB.G
mice developed symptoms ofAbelson disease. When analyzed for 6C3Ag, bone
marrow, lymph node, and spleen cells from such mice were found to express
high levels of the antigen (Fig. 3). Therefore, we have not yet found a mouse
with Abelson disease that lacks a population of cells expressing high levels of
6C3Ag, regardless ofgenetic resistance or susceptibility.
Discussion
Genetically linked susceptibility to A-MuLV(Mo) leukemogenesis in vivo ap-
pears to involve two independent loci, either ofwhich modify the development
of leukemia rather than cause regression of established tumors (1). Thus these
restrictions probably limit events before the emergence offrankly leukemic cells.44
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FIGURE 3.
￿
The appearance of 6C3Aghi cells in CxB.G mouse lymphoid tissues correlates
with disease symptoms. 8 wk after i.v. injection of A-MuLV(Mo) into CxB.G mice some
developed typical disease symptoms. This observed longer latency is consistent with that
observed previously (1). A mouse with symptoms but still alive was killed and all tissues were
stained with mAb 6C3. This figure represents the FACS profiles derived from bone marrow,
lymph node, and spleen cell suspensions. There was no detectable staining in any secondary
lymphoid organ from animals not injected with the virus (data not shown). In addition, no
6C3Agh' cellswere detected in the thymus of the animal represented here.
After integration ofA-MuLV into host cells, viral-encoded gag-abl fusion protein
is expressed as a cytoplasmic, plasma membrane-associated tyrosine kinase. This
expression of the v-abl oncogene is not sufficient for full neoplastic transforma-
tion in vitro in liquid cultures, as proliferation of cells expressing gag-abl is
dependent on bone marrow-derived stromal feeder cells characteristic of the
Whitlock-Witte in vitro pre-B culturesystem (6). Thesegag-abl + cells are 6C3Ag
at this stage ofdevelopment (2). Fully malignant, feeder layer-independent pre-
B leukemias emerge; these cells either are 6C3Agh' or give rise to progeny that
become 6C3Agh' (G. F. Tidmarsh, manuscript in preparation). Incidentally, the
cloned stromal cells from Whitlock-Witte pre-B cultures that support growth of
premalignant gag-abl' 6C3Ag- cells are themselves synthesizing and expressing
high levels of cell surface 6C3Ag, providing evidence that the expression of
6C3Ag is linked to growth control ofboth normal and preneoplastic pre-B cells
(Whitlock, Tidmarsh, Muller-Sieburg, and Weissman, manuscript submitted for
publication) . Herein, we sought evidence as to whether genetically limited
susceptibility to A-MuLV(Mo)-induced pre-B leukemia acted before or after the
stage of6C3Ag expression . Mouse strains genetically resistant to A-MuLV(Mo)
develop neither 6C3Ag+ bone marrow cells nor Abelson leukemias, consistent
with the model that restriction occurs before 6C3Ag expression at some earlier
stage ofneoplastic progression, perhaps aftergag-abl expression in infected cells.
It has recently (7) been shown that several other viral oncogenes, when
expressed as cytoplasmic, membrane-associated phosphokinases, can induce pre-
B leukemiasafterinfection ofbone marrow cells in vitro witha murine retrovirus
vector (7); these include abl, src, fes, ras, and erb B. These pre-B tumors also
express high levels ofsurface 6C3Ag(H. C. Morse, K. L. Holmes, W. Y. Langdon,
T. N. Fredrickson, J. W. Hartley, J. H. Pierce, G. F. Tidmarsh, M. O. Dailey, I.
L. Weissman, manuscript submitted for publication; andJ. Adams, W. Langdon,
A. Harris, and S. Cory, personal communication). It will be interesting to test1360
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whether any (or all) ofthese are also genetically restricted as leukemogens in the
mouse strains resistant to A-MuLV(Mo). In contrast to these phosphokinase
oncogenes, v-myc-containing vectors induce and c-myc-transgenic mice with im-
munoglobulin H chain enhancer sequences develop marrow-derived pre-B leu-
kemias, and none ofthese are 6C3Ag+. It will be interesting to see whether these
tumors also differ from the phosphokinase oncogene leukemogens by the above-
described mouse strain genetic restrictions.
In these and previously published experiments (2, 3) there is an absolute
correlation between induction of Abelson disease and expression ofcell surface
6C3Ag onpresumably malignantcells. This is consistent with the hypothesis that
expression of high levels of 6C3Ag on pre-B/early B cells is a marker for the
malignant stage ofneoplastic progression after A-MuLV(Mo) infection, and that
proteins bearing 6C3Ag are directly involved in expression of the malignant
phenotype in these cells.
The observation that 6C3Ag is undetectable in secondary lymphoid organs in
the absence of disease, yet is readily detectable in these organs when they are
lymphomatous makes the antigen an excellent marker for diagnosis of disease.
Current efforts are directed toward developing polyclonal antisera and mAbs
that recognize an analogous molecule on human tumors. Identification of such
a determinant may be ofpotential benefit for diagnosis and/or therapy of pre-B
cell or non-B/non-T cell leukemias and lymphomas in man.
Summary
Mice genetically susceptible or genetically resistant to the leukemogenic effects
of A-MuLV(Mo) were tested for their expression of the B-lineage neoplastic
transformation-associated antigen, 6C3Ag. Genetically resistant inbred strains
and recombinant inbred lines developed neither cells expressing high levels of
6C3Ag (6C3Ag") in their hematolymphoid tissues nor Abelson leukemias. Ge-
netically susceptible inbred strains and recombinant inbred lines developed high
percentages of 6C3Ag" hematolymphoid cells concomitant with development of
Abelson leukemias and lymphomas. Thus the genetically-determined resistance
to A-MuLV(Mo) leukemogenesis appears to act at some step(s) after virus
infection but before the stage of malignant progression, which is marked by
6C3Ag expression.
Received for publication 14 July 1986.
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